The effects of short-term hormone replacement therapy on long-term bone mineral density

被引:16
作者
Middleton, E. T. [1 ]
Steel, S. A. [1 ]
机构
[1] Hull Royal Infirm, Ctr Metab Bone Dis, Kingston Upon Hull HU3 2RW, N Humberside, England
关键词
bone mineral density; perimenopause; hormone replacement therapy;
D O I
10.1080/13697130701370435
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Introduction Short-term hormone replacement therapy (HRT) relieves menopausal symptoms and increases bone mineral density (BMD), but bone loss reoccurs upon discontinuation. This study assesses whether short-term HRT provides long-term BMD benefits. Method This was a prospective study of women aged 50-54 years followed up for 9 years. Women were categorized into three groups according to the treatment they received: No-HRT (n = 340), Short-term HRT (2-4 years, n = 60), and Long-term HRT (9 years, n = 18 7). Results BMD increased significantly at the hip (2.4%, p < 0.001) and spine (8.0%, p < 0.001) over 9 years in the Long-term HRT group. Women without treatment lost BMD at the hip (-4.2%, p < 0.001) and spine (-3.5%, p < 0.001). Women in the Short-term HRT group had no significant loss of BMD at the hip (- 1.6%, p = 0.08) or spine (-1.4%, p=0.18) over 9 years. BMD in the Short-term HRT group was significantly higher at 9 years than in the No-HRT group at both spine (difference 0.023 g/cm(2), p = 0.048) and hip (difference 0.016 g/cm(2), p = 0.042). Conclusion After 9 years, women who had taken short-term HRT had no significant loss of BMD and were better off in terms of BMD than those left untreated. Short-term HRT in the early postmenopausal period provides long-term BMD benefits.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 20 条
[1]
Bias from. requiring explicit consent from all participants in observational research: Prospective, population based study [J].
Al-Shahi, R ;
Vousden, C ;
Warlow, C .
BRITISH MEDICAL JOURNAL, 2005, 331 (7522) :942-945
[2]
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[3]
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures:: the PERF study [J].
Bagger, YZ ;
Tankó, LB ;
Alexandersen, P ;
Hansen, HB ;
Mollgaard, A ;
Ravn, P ;
Qvist, P ;
Kanis, JA ;
Christiansen, C .
BONE, 2004, 34 (04) :728-735
[4]
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[5]
Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[6]
Effects of estrogen plus progestin on risk of fracture and bone mineral density - The Women's Health Initiative randomized trial [J].
Cauley, JA ;
Robbins, J ;
Chen, Z ;
Cummings, SR ;
Jackson, RD ;
LaCroix, AZ ;
LeBoff, M ;
Lewis, CE ;
McGowan, J ;
Neuner, J ;
Pettinger, M ;
Stefanick, ML ;
Wactawski-Wende, J ;
Watts, NB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (13) :1729-1738
[7]
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial [J].
Delmas, PD ;
Ensrud, KE ;
Adachi, JD ;
Harper, KD ;
Sarkar, S ;
Gennari, C ;
Reginster, JY ;
Pols, HAP ;
Recker, RR ;
Harris, ST ;
Wu, WT ;
Genant, HK ;
Black, DM ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3609-3617
[8]
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial [J].
Greenspan, SL ;
Emkey, RD ;
Bone, HG ;
Weiss, SR ;
Bell, NH ;
Downs, RW ;
McKeever, C ;
Miller, SS ;
Davidson, M ;
Bolognese, MA ;
Mulloy, AL ;
Heyden, N ;
Wu, M ;
Kaur, A ;
Lombardi, A .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (11) :875-883
[9]
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the women's health initiative randomized trial [J].
Jackson, Rebecca D. ;
Wactawski-Wende, Jean ;
LaCroix, Andrea Z. ;
Pettinoer, Mary ;
Yood, Robert A. ;
Watts, Nelson B. ;
Robbins, John A. ;
Lewis, Cora E. ;
Beresford, Shirley A. A. ;
Ko, Marcia G. ;
Naughton, Michelle J. ;
Satterfield, Suzanne ;
Bassford, Tamsen .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (06) :817-828
[10]
Recruiting patients to medical research: double blind randomised trial of "opt-in" versus "opt-out" strategies [J].
Junghans, C ;
Feder, G ;
Hemingway, H ;
Timmis, A ;
Jones, M .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7522) :940-942